Humoral and cellular immune response and the safety of third SARS-CoV-2 mRNA vaccine with longer interval after the second vaccination in kidney transplant recipients

被引：8

作者：

Takai, Satoshi ^{[1
]}

Nishida, Hayato ^{[1
]}

Ito, Hiromi ^{[1
]}

Fukuhara, Hiroki ^{[1
]}

Nawano, Takaaki ^{[2
]}

Narisawa, Takafumi ^{[1
]}

Kanno, Hidenori ^{[1
]}

Yagi, Mayu ^{[1
]}

Yamagishi, Atsushi ^{[1
]}

Sakurai, Toshihiko ^{[1
]}

Naito, Sei ^{[1
]}

Kato, Tomoyuki ^{[1
]}

Morikane, Keita ^{[3
]}

Tsuchiya, Norihiko ^{[1
]}

机构：

[1] Yamagata Univ, Dept Urol, Fac Med, Yamagata, Japan

[2] Yamagata Univ, Dept Cardiol Pulmonol & Nephrol, Fac Med, Yamagata, Japan

[3] Yamagata Univ Hosp, Div Clin Lab & Infect Control, Yamagata, Japan

来源：

FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷

关键词：

kidney transplantation; rituximab; COVID-19; SARS-CoV-2; mRNA vaccine; COVID-19; VACCINE; ANTIBODY;

D O I：

10.3389/fimmu.2022.1050211

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We evaluated the humoral and cellular immune responses and safety of the third severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine with a longer interval after the second vaccination in kidney transplant recipients (KTRs). We enrolled 54 kidney transplant recipients without a history of coronavirus disease 2019 (COVID-19), who received a third dose of the vaccine. We assessed anti-SARS-CoV-2 spike antibody and antigen-specific T cells using enzyme-linked immunospot (ELISpot) against the spike protein at baseline, after the second vaccination, and after the third vaccination. We also evaluated the adverse events related to each dose of the vaccine. The duration between the second and third vaccinations was 7 +/- 1 month. All 17 (100%) KTRs with anti-SARS-CoV-2 antibody positivity after the second vaccination and 27 of 37 (73%) KTRs without anti-SARS-CoV-2 antibody positivity after the second vaccination were positive for anti-SARS-CoV-2 antibodies (p=0.022). Anti-SARS-CoV-2 antibody titers were significantly higher than those after the second vaccination (p<0.001). Age >= 60 years and lymphocyte count < 1150/mm(3) were confirmed as risk factors for anti-SARS-CoV-2 antibody negativity after the third vaccination in multivariate regression analysis. ELISpot cytokine activities were positive after the third vaccination in 26 of 29 (90%) KTRs with ELISpot cytokine activity positivity after the second vaccination and 12 of 24 (50%) KTRs without ELISpot cytokine activity after the second vaccination. The rate of change in cytokine activity after the third vaccination was significantly higher than that after the second vaccination (p<0.001). Only lymphocyte counts less than 1150/mm(3) were confirmed as risk factors for ELISpot cytokine activity negativity in the multivariate regression analysis. Systemic adverse events classified as greater than moderate did not differ for each vaccine dose. None of the patients showed clinical symptoms of acute rejection. The third SARS-CoV-2 mRNA vaccine administration, with a longer interval after the second vaccination, improved humoral and cellular immune responses to SARS-CoV-2 mRNA vaccines without severe adverse effects in the KTRs.

引用

页数：11

共 30 条

[1] Antibody Response to a Fourth Dose of a SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series [J].

Alejo, Jennifer L. ;

Mitchell, Jonathan ;

Chiang, Teresa P. -Y. ;

Abedon, Aura T. ;

Boyarsky, Brian J. ;

Avery, Robin K. ;

Tobian, Aaron A. R. ;

Levan, Macey L. ;

Massie, Allan B. ;

Garonzik-Wang, Jacqueline M. ;

Segev, Dorry L. ;

Werbel, William A. .

TRANSPLANTATION, 2021, 105 (12) :E280-E281

[2] Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel [J].

Bar-On, Yinon M. ;

Goldberg, Yair ;

Mandel, Micha ;

Bodenheimer, Omri ;

Freedman, Laurence ;

Kalkstein, Nir ;

Mizrahi, Barak ;

Alroy-Preis, Sharon ;

Ash, Nachman ;

Milo, Ron ;

Huppert, Amit .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (15) :1393-1400

[3] The Impact of Vaccination on Incidence and Outcomes of SARS-CoV-2 Infection in Patients with Kidney Failure in Scotland [J].

Bell, Samira ;

Campbell, Jacqueline ;

Lambourg, Emilie ;

Watters, Chrissie ;

O'Neil, Martin ;

Almond, Alison ;

Buck, Katharine ;

Carr, Edward J. ;

Clark, Laura ;

Cousland, Zoe ;

Findlay, Mark ;

Joss, Nicola ;

Metcalfe, Wendy ;

Petrie, Michaela ;

Spalding, Elaine ;

Traynor, Jamie P. ;

Sanu, Vinod ;

Thomson, Peter ;

Methven, Shona ;

Mark, Patrick B. .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (04) :677-686

[4] Impact of tozinameran (BNT162b2) mRNA vaccine on kidney transplant and chronic dialysis patients: 3-5 months follow-up [J].

Ben-Dov, Iddo Z. ;

Oster, Yonatan ;

Tzukert, Keren ;

Alster, Talia ;

Bader, Raneem ;

Israeli, Ruth ;

Asayag, Haya ;

Aharon, Michal ;

Burstein, Ido ;

Pri-Chen, Hadas ;

Imam, Ashraf ;

Abel, Roy ;

Levi, Irit Mor-Yosef ;

Khalaileh, Abed ;

Oiknine-Djian, Esther ;

Bloch, Aharon ;

Wolf, Dana G. ;

Elhalel, Michal Dranitzki .

JOURNAL OF NEPHROLOGY, 2022, 35 (01) :153-164

[5] Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses [J].

Benotmane, Ilies ;

Gautier, Gabriela ;

Perrin, Peggy ;

Olagne, Jerome ;

Cognard, Noelle ;

Fafi-Kremer, Samira ;

Caillard, Sophie .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (11) :1063-1065

[6] Antibody and T-cell response to a third dose of SARS-CoV-2 mRNA BNT162b2 vaccine in kidney transplant recipients [J].

Bertrand, Dominique ;

Hamzaoui, Mouad ;

Lemee, Veronique ;

Lamulle, Julie ;

Laurent, Charlotte ;

Etienne, Isabelle ;

Lemoine, Mathilde ;

Lebourg, Ludivine ;

Hanoy, Melanie ;

Le Roy, Frank ;

Nezam, Dorian ;

Farce, Fabienne ;

Plantier, Jean-Christophe ;

Boyer, Olivier ;

Guerrot, Dominique ;

Candon, Sophie .

KIDNEY INTERNATIONAL, 2021, 100 (06) :1337-1340

[7] Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series [J].

Caillard, Sophie ;

Thaunat, Olivier ;

Benotmane, Ilies ;

Masset, Christophe ;

Blancho, Gilles .

ANNALS OF INTERNAL MEDICINE, 2022, 175 (03) :455-+

[8] COVID-19 vaccination in kidney transplant recipients [J].

Caillard, Sophie ;

Thaunat, Olivier .

NATURE REVIEWS NEPHROLOGY, 2021, 17 (12) :785-787

[9] Occurrence of severe COVID-19 in vaccinated transplant patients [J].

Caillard, Sophie ;

Chavarot, Nathalie ;

Bertrand, Dominique ;

Kamar, Nassim ;

Thaunat, Olivier ;

Moal, Valerie ;

Masset, Christophe ;

Hazzan, Marc ;

Gatault, Philippe ;

Sicard, Antoine ;

Chemouny, Jonathan M. ;

Rerolle, Jean Philippe ;

Colosio, Charlotte ;

Francois, Helene ;

Bamoulid, Jamal ;

Bouvier, Nicolas ;

Duveau, Agnes ;

Anglicheau, Dany ;

Blancho, Gilles .

KIDNEY INTERNATIONAL, 2021, 100 (02) :477-479

[10] Weak antibody response to three doses of mRNA vaccine in kidney transplant recipients treated with belatacept [J].

Chavarot, Nathalie ;

Morel, Antoine ;

Leruez-Ville, Marianne ;

Vilain, Estelle ;

Divard, Gillian ;

Burger, Carole ;

Serris, Alexandra ;

Sberro-Soussan, Rebecca ;

Martinez, Frank ;

Amrouche, Lucile ;

Bererhi, Lynda ;

Lanternier, Fanny ;

Legendre, Christophe ;

Zuber, Julien ;

Anglicheau, Dany ;

Scemla, Anne .

AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 (12) :4043-4051

← 1 2 3 →